Zogenix To Pay $250m Upfront To Buy Modis For Ultra-Orphan Drug

The takeover will diversify Zogenix’s pipeline through the addition of MT1621, a drug that improved the probability of survival in patients with an inherited mitochondrial DNA depletion disorder.

Close up business man signing contract making a deal, classic business
• Source: Shutterstock

More from Business

More from Scrip